文献速递肾癌与肾肿瘤

冷冻消融相比肾部分切除术使非转移性pT1b肾癌患者具有更高的癌症特异性死亡率

Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer.
PubMed 文献 · J Urol · 2019-07-26

基于2004至2015年SEER数据库5763例pT1b非转移性肾细胞癌患者,比较冷冻消融与肾部分切除术后的癌症特异性死亡率。经倾向性评分匹配及竞争风险回归分析,冷冻消融后5年癌症特异性死亡率为肾部分切除术的2.5倍(p=0.03),其他原因死亡率两组相似(HR 1.45,p=0.12)。作者认为该观察结果应解读为临床试验或机构方案外冷冻消融的禁忌证。

要点

  • pT1b非转移性肾细胞癌冷冻消融后5年癌症特异性死亡率为肾部分切除术的2.5倍(p=0.03)。
  • 匹配及调整后5年其他原因死亡率冷冻消融与肾部分切除术相似(HR 1.45,p=0.12)。
  • 作者认为该结果应解读为临床试验或机构方案外冷冻消融的禁忌证。

核心结论

  • pT1b肾细胞癌患者接受冷冻消融后癌症特异性死亡率增加2.5倍。
  • 作者认为该观察结果应解读为临床试验或机构方案外冷冻消融的禁忌证。

研究设计与样本

  • 基于2004至2015年SEER数据库识别5763例接受冷冻消融或肾部分切除术的T1b肿瘤患者。
  • 采用多变量逻辑回归模型预测冷冻消融vs肾部分切除术,并按1:2比例进行倾向性评分匹配。
  • 匹配后使用累积发生率图和竞争风险回归检验癌症特异性死亡率与其他原因死亡率的差异。

主要发现

  • 冷冻消融组242例,肾部分切除术组5521例;冷冻消融组年龄更大、肿瘤更小、低或未知分级未分类肾细胞癌更常见。
  • 中位随访38个月。
  • 多变量逻辑回归中,更晚的患者年龄是冷冻消融vs肾部分切除术的独立预测因素(OR 1.03;p=0.007)。
  • 倾向性评分匹配及其他原因死亡率调整后,冷冻消融后5年癌症特异性死亡率为肾部分切除术的2.5倍(p=0.03)。
  • 倾向性评分匹配及癌症特异性死亡率调整后,冷冻消融后5年其他原因死亡率与肾部分切除术相似(HR 1.45,p=0.12)。

临床怎么用

  • 作者认为该观察结果应解读为临床试验或机构方案外冷冻消融的禁忌证。

局限性

  • 本研究的主要局限性是缺乏复发和转移进展数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Cryoablation is done in select patients with pT1b nonmetastatic renal cell carcinoma without convincing proof of efficacy. Our aim was to test for differences in the cancer specific mortality rate for cryoablation and partial nephrectomy in T1b nonmetastatic renal cell carcinoma cases. MATERIALS AND METHODS: In the 2004 to 2015 SEER (Surveillance, Epidemiology, and End Results) database we identified 5,763 patients with a T1b tumor treated with cryoablation or partial nephrectomy. Modeling relied on multivariable logistic regression models predicting cryoablation vs partial nephrectomy. After 1:2 ratio propensity score matching between patients treated with cryoablation vs partial nephrectomy we used cumulative incidence plot and competing risks regression to test differences in cancer specific mortality and other cause mortality rates. RESULTS: Relative to the 5,521 patients who underwent partial nephrectomy the 242 treated with cryoablation were older, had smaller tumors and more frequently harbored unclassified renal cell carcinoma of low or unknown grade. Median followup was 38 months. In multivariable logistic regression models predicting cryoablation vs partial nephrectomy more advanced patient age was an independent predictor (OR 1.03; p=0.007). After propensity score matching and other cause mortality adjustment the 5-year cancer specific mortality rate was 2.5-fold higher after cryoablation than after partial nephrectomy (p=0.03). Conversely after propensity score matching and cancer specific mortality adjustment the 5-year other cause mortality rate was similar to that of partial nephrectomy after cryoablation (HR 1.45, p=0.12). The major limitation of this study was the lack of recurrence and metastatic progression data. CONCLUSIONS: The current findings demonstrated a 2.5-fold increase in cancer specific mortality when cryoablation was performed in patients with pT1b renal cell carcinoma. This observation should be interpreted as a contraindication to cryoablation outside clinical trials or institutional protocols.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Pecoraro A, Palumbo C, Knipper S, et al. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. J Urol. 2019. PMID: 31347950. doi:10.1097/JU.0000000000000460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。